Could older UC patients ditch risky meds for a simpler option?
NCT ID NCT07248644
First seen Jan 04, 2026 · Last updated Jun 22, 2026 · Updated 27 times
Summary
This study looks at whether older adults (60+) with ulcerative colitis who are in long-term remission can safely stop taking thiopurines (azathioprine or 6-mercaptopurine) and rely only on high-dose mesalazine. Thiopurines carry increased risks of infection and cancer with age, so switching may be safer. The trial will follow 304 participants for 24 months to compare relapse rates between those who stop thiopurines and those who continue.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS (UC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
mesalazine (high-dose oral, ≥3 g/day) and thiopurines (azathioprine or 6-mercaptopurine)
What this could lead to
If successful, this could show that older patients with ulcerative colitis can safely switch to a simpler, lower-risk medication regimen without losing remission.
What could go wrong
This is a Phase 4 trial, so the drugs are already approved, but it is still possible that stopping thiopurines leads to more relapses. The study is also open-label, which may introduce bias.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.